Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- 1
- The Pathogenesis of MASLD
- 2
- Diagnosis
- (1)
- Collagens (procollagen I and III, released in serum during deposition and remodeling of the extracellular matrix; collagen IV, released during the degradation and remodeling of the extracellular matrix).
- (2)
- Glycoproteins and polysaccharides (hyaluronic acid, laminin, tenascin, YKL-40).
- (3)
- Collagenases and their inhibitors; metalloproteinases (MMPs) and their inhibitors (TIMPs).
- (4)
- Cytokines (TNF-a, IL-6, IL-8, IL-1B, and IL-10) [23].
- 3
- Therapy
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Han, S.K.; Baik, S.K.; Kim, M.Y. Non-alcoholic fatty liver disease: Definition and subtypes. Clin. Mol. Hepatol. 2023, 29, S5–S16. [Google Scholar] [CrossRef] [PubMed]
- Nascimbeni, F.; Ballestri, S.; Machado, M.V.; Mantovani, A.; Cortez-Pinto, H.; Targher, G.; Lonardo, A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Rev. Gastroenterol. Hepatol. 2018, 12, 351–367. [Google Scholar] [CrossRef] [PubMed]
- Eslam, M.; Sanyal, A.J.; George, J.; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020, 158, 1999–2014.e1. [Google Scholar] [CrossRef] [PubMed]
- Rinella, M.E.; Lazarus, J.V.; Ratziu, V.; Francque, S.M.; Sanyal, A.J.; Kanwal, F.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 2023, 79, 1542–1556. [Google Scholar] [CrossRef] [PubMed]
- Rinella, M.E.; Sookoian, S. From NAFLD to MASLD: Updated Naming and Diagnosis Criteria for Fatty Liver Disease. J. Lipid Res. 2024, 65, 100485. [Google Scholar] [CrossRef] [PubMed]
- Ilagan-Ying, Y.C.; Banini, B.A.; Do, A.; Lam, R.; Lim, J.K. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Curr. Gastroenterol. Rep. 2023, 25, 213–224. [Google Scholar] [CrossRef] [PubMed]
- De, A.; Bhagat, N.; Mehta, M.; Taneja, S.; Duseja, A. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. J. Hepatol. 2023, 80, e61–e62. [Google Scholar] [CrossRef] [PubMed]
- Duan, Y.; Pan, X.; Luo, J.; Xiao, X.; Li, J.; Bestman, P.L.; Luo, M. Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease. Front. Immunol. 2022, 13, 880298. [Google Scholar] [CrossRef] [PubMed]
- Geng, Y.; Faber, K.N.; de Meijer, V.E.; Blokzijl, H.; Moshage, H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol. Int. 2021, 15, 21–35. [Google Scholar] [CrossRef]
- Mann, J.P.; Raponi, M.; Nobili, V. Clinical implications of understanding the association between oxidative stress and pediatric NAFLD. Expert Rev. Gastroenterol. Hepatol. 2017, 11, 371–382. [Google Scholar] [CrossRef]
- Del Chierico, F.; Nobili, V.; Vernocchi, P.; Russo, A.; De Stefanis, C.; Gnani, D.; Furlanello, C.; Zandonà, A.; Paci, P.; Capuani, G.; et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 2017, 65, 451–464. [Google Scholar] [CrossRef] [PubMed]
- Khanmohammadi, S.; Kuchay, M.S. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease. Pharmacol. Res. 2022, 185, 106507. [Google Scholar] [CrossRef] [PubMed]
- Nobili, V.; Alisi, A.; Mosca, A.; Della Corte, C.; Veraldi, S.; De Vito, R.; De Stefanis, C.; D’Oria, V.; Jahnel, J.; Zohrer, E.; et al. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. Liver Int. 2018, 38, 342–349. [Google Scholar] [CrossRef] [PubMed]
- Carpino, G.; Pastori, D.; Baratta, F.; Overi, D.; Labbadia, G.; Polimeni, L.; Di Costanzo, A.; Pannitteri, G.; Carnevale, R.; Del Ben, M.; et al. PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: A possible role for oxidative stress. Sci. Rep. 2017, 7, 15756. [Google Scholar] [CrossRef] [PubMed]
- Vespasiani-Gentilucci, U.; Gallo, P.; Porcari, A.; Carotti, S.; Galati, G.; Piccioni, L.; De Vincentis, A.; Dell’unto, C.; Vorini, F.; Morini, S.; et al. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand. J. Gastroenterol. 2016, 51, 967–973. [Google Scholar] [CrossRef] [PubMed]
- Vos, M.B.; Abrams, S.H.; Barlow, S.E.; Caprio, S.; Daniels, S.R.; Kohli, R.; Mouzaki, M.; Sathya, P.; Schwimmer, J.B.; Sundaram, S.S.; et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J. Pediatr. Gastroenterol. Nutr. 2017, 64, 319–334. [Google Scholar] [CrossRef] [PubMed]
- Ajmera, V.; Loomba, R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol. Metab. 2021, 50, 101167. [Google Scholar] [CrossRef] [PubMed]
- Chandra Kumar, C.V.; Skantha, R.; Chan, W.K. Non-invasive assessment of metabolic dysfunction-associated fatty liver disease. Ther. Adv. Endocrinol. Metab. 2022, 13, 20420188221139614. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.; Vali, Y.; Boursier, J.; Spijker, R.; Anstee, Q.M.; Bossuyt, P.M.; Zafarmand, M.H. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int. 2020, 41, 261–270. [Google Scholar] [CrossRef]
- Ampuero, J.; Pais, R.; Aller, R.; Gallego-Durán, R.; Crespo, J.; García-Monzón, C.; Boursier, J.; Vilar, E.; Petta, S.; Zheng, M.-H.; et al. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clin. Gastroenterol. Hepatol. 2019, 18, 216–225.e5. [Google Scholar] [CrossRef]
- Prasoppokakorn, T.; Chan, W.-K.; Wong, V.W.-S.; Pitisuttithum, P.; Mahadeva, S.; Mustapha, N.R.N.; Wong, G.L.-H.; Leung, H.H.-W.; Sripongpun, P.; Treeprasertsuk, S. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease. World J. Gastroenterol. 2022, 28, 1563–1573. [Google Scholar] [CrossRef]
- Mosca, A.; Della Volpe, L.; Alisi, A.; Veraldi, S.; Francalanci, P.; Maggiore, G. Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease. Front. Pediatr. 2022, 10, 885576. [Google Scholar] [CrossRef] [PubMed]
- Loomba, R.; Adams, L.A. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020, 69, 1343–1352. [Google Scholar] [CrossRef]
- Dellavance, A.; Fernandes, F.; Shimabokuro, N.; Latini, F.; Baldo, D.; Barreto, J.A.; Marvulle, V.; Andrade, L.E.; Ferraz, M.L. Enhanced liver fibrosis (ELF) score: Analytical performance and distribution range in a large cohort of blood donors. Clin. Chim. Acta 2016, 461, 151–155. [Google Scholar] [CrossRef] [PubMed]
- Vali, Y.; Lee, J.; Boursier, J.; Spijker, R.; Löffler, J.; Verheij, J.; Brosnan, M.J.; Böcskei, Z.; Anstee, Q.M.; LITMUS Systematic Review Team; et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J. Hepatol. 2020, 73, 252–262. [Google Scholar] [CrossRef] [PubMed]
- Genovese, F.; Rasmussen, D.G.K.; Karsdal, M.A.; Jesky, M.; Ferro, C.; Fenton, A.; Cockwell, P. Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients. Clin. Kidney J. 2020, 14, 593–601. [Google Scholar] [CrossRef]
- Daniels, S.J.; Leeming, D.J.; Eslam, M.; Hashem, A.M.; Nielsen, M.J.; Krag, A.; Karsdal, M.A.; Grove, J.I.; Neil Guha, I.; Kawaguchi, T.; et al. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients with NAFLD and Advanced Fibrosis. Hepatology 2019, 69, 1075–1086. [Google Scholar] [CrossRef] [PubMed]
- Mosca, A.; Mantovani, A.; Crudele, A.; Panera, N.; Comparcola, D.; De Vito, R.; Bianchi, M.; Byrne, C.D.; Targher, G.; Alisi, A. Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease. Front. Pediatr. 2022, 10, 917714. [Google Scholar] [CrossRef]
- Myint, M.; Oppedisano, F.; De Giorgi, V.; Kim, B.M.; Marincola, F.M.; Alter, H.J.; Nesci, S. Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions. J. Transl. Med. 2023, 21, 757. [Google Scholar] [CrossRef]
- Crudele, L.; Garcia-Irigoyen, O.; Cariello, M.; Piglionica, M.; Scialpi, N.; Florio, M.; Piazzolla, G.; Suppressa, P.; Sabbà, C.; Gadaleta, R.M.; et al. Total serum FGF-21 levels positively relate to visceral adiposity differently from its functional intact form. Front. Endocrinol. 2023, 14, 1159127. [Google Scholar] [CrossRef]
- Hua, M.C.; Huang, J.L.; Hu, C.C.; Yao, T.C.; Lai, M.W. Including Fibroblast Growth Factor-21 in Combined Biomarker Panels Improves Predictions of Liver Steatosis Severity in Children. Front. Pediatr. 2019, 7, 420. [Google Scholar] [CrossRef] [PubMed]
- Wu, G.; Li, H.; Fang, Q.; Zhang, J.; Zhang, M.; Zhang, L.; Wu, L.; Hou, X.; Lu, J.; Bao, Y.; et al. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease. Sci. Rep. 2017, 7, 5095. [Google Scholar] [CrossRef] [PubMed]
- Jang, W.; Song, J.S. Non-Invasive Imaging Methods to Evaluate Non-Alcoholic Fatty Liver Disease with Fat Quantification: A Review. Diagnostics 2023, 13, 1852. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.N.; Fowler, K.J.; Ozturk, A.; Potu, C.K.; Louie, A.L.; Montes, V.; Henderson, W.C.; Wang, K.; Andre, M.P.; Samir, A.E.; et al. Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography. J. Magn. Reson. Imaging 2019, 51, 25–42. [Google Scholar] [CrossRef] [PubMed]
- Della Corte, C.; Mosca, A.; Ionata, A.; Nobili, V. Docosahexaenoic Acid and Its Role in G-Protein-Coupled Receptor 120 Activation in Children Affected by Nonalcoholic Fatty Liver Disease. Endocr. Dev. 2016, 30, 29–36. [Google Scholar] [CrossRef] [PubMed]
- Della Corte, C.; Carpino, G.; De Vito, R.; De Stefanis, C.; Alisi, A.; Cianfarani, S.; Overi, D.; Mosca, A.; Stronati, L.; Cucchiara, S.; et al. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. PLoS ONE 2016, 11, e0168216. [Google Scholar] [CrossRef] [PubMed]
- Nobili, V.; Alisi, A.; Mosca, A.; Crudele, A.; Zaffina, S.; Denaro, M.; Smeriglio, A.; Trombetta, D. The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment? Antioxid. Redox Signal. 2019, 31, 127–133. [Google Scholar] [CrossRef] [PubMed]
- Younossi, Z.M.; Ratziu, V.; Loomba, R.; Rinella, M.; Anstee, Q.M.; Goodman, Z.; Bedossa, P.; Geier, A.; Beckebaum, S.; Newsome, P.N.; et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019, 394, 2184–2196, Erratum in Lancet 2020, 396, 312; Erratum in Lancet 2021, 397, 2336. [Google Scholar] [CrossRef]
- Rupasinghe, K.; Hind, J.; Hegarty, R. Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children. J. Pediatr. Gastroenterol. Nutr. 2023, 77, 583–591. [Google Scholar] [CrossRef]
NCT Number | Title | Status | Study Results | Conditions | Interventions | Locations | |
---|---|---|---|---|---|---|---|
1 | NCT01529268 | Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children | Completed | Has results | Non-alcoholic fatty liver disease (NAFLD) | -Drug: DR cysteamine bitartrate capsule -Other: DR cysteamine bitartrate placebo | University of California, San Diego, San Diego, California, United States |
2 | NCT01913470 | Study of Losartan in the Treatment of NAFLD in Children | Completed | Has results | NAFLD | Drug: Losartan | Emory University/Children’s Healthcare of Atlanta, Atlanta, Georgia, United States |
3 | NCT00063635 | Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) | Completed | Has results | Fatty liver | -Drug: Metformin -Dietary supplement: vitamin E -Drug: matching placebo | -University of California, San Diego, San Diego, California, United States -University of California, San Francisco, San Francisco, California, United States |
4 | NCT02134522 | The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease | Terminated | Has results | Non-alcoholic fatty liver disease | Device: continuous positive airway pressure (CPAP). | Yale University, New Haven, Connecticut, United States |
5 | NCT04415112 | Mediterranean Diet Treatment for NAFLD | Completed | No results available | -Mediterranean diet | -Behavioral: Mediterranean diet -Behavioral: low-fat diet | Ulas Emre Akbulut, Antalya, Turkey |
6 | NCT02842567 | Hydroxytyrosol and Vitamin E in Pediatric NASH | Completed | No results available | NAFLD | -Drug: Hydroxytyrosol plus vitamin E -Drug: placebo | -Hepatometabolic Department, Bambino Gesù Children’s Hospital, Rome, Italy |
7 | NCT01934777 | Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis | Completed | No results available | -Fatty liver -Liver fibrosis | -Drug: Docosahexaenoic Acid plus vitamin E plus choline Drug: placebo pearls | Bambino Gesù Hospital and Research Institute, Rome, Rome, Italy, Italy |
8 | NCT01285362 | Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study | Completed | Has results | -Non-alcoholic fatty liver disease | -Drug: fish oil supplementation -Drug: placebo supplementation | -Irving Clinical Research Center (GCRC) at Columbia University Medical Center, New York, New York, United States |
9 | NCT02258126 | Effect of Exercise on Hepatic Fat in Overweight Children | Completed | No results available | -Non-alcoholic fatty liver disease -Obesity -Metabolic syndrome | -Other: multidisciplinary intervention program | -Pediatric Endocrinology Unit of the University Hospital of Araba (HUA), Vitoria-Gasteiz, Araba, Spain |
10 | NCT00655018 | Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) | Completed | No results available | -Inflammation -Fibrosis -Insulin resistance | -Dietary supplement: vitamin treatment (alpha tocopherol plus ascorbic acid) -Dietary supplement: placebo | -Dept. Of HepatoGastoEnterology and Nutrition, Liver Unit, Rome, Italy |
11 | NCT01547910 | Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children | Completed | No results available | Non-alcoholic fatty liver disease | Dietary supplement: fish oil | Children’s Memorial Health Institute, Poland |
12 | NCT01553500 | Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease | Completed | No Results Available | -Metabolic syndrome -Non-alcoholic fatty liver disease -Insulin resistance | -Dietary supplement: glucomannan -Behavioral: lifestyle intervention | -Bambino Gesù Children’s Hospital and Research Institute, Rome, Italy |
13 | NCT00823277 | Metabolic Syndrome and Gen-polymorphs Influence on Weightloss Among Children in Treatment for Overweight | Completed | No results available | -Childhood Obesity -NAFLD (Non-alcoholic fatty liver disease) | -Other: chronic care multidisciplinary intervention of childhood obesity | -The Children’s Obesity Clinic, Paediatric Department, University Hospital Holbaek, Region Zealand, University of Copenhagen, Holbaek, Denmark |
14 | NCT01556113 | Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease | Completed | No results available | -Non-alcoholic fatty liver disease -Steatohepatitis -Hypertriglyceridemia | -Other: Omega diet | -Yale School of Medicine, New Haven, Connecticut, United States |
15 | NCT02117700 | Fatty Liver Disease in Obese Children | Completed | No results available | -Obesity -Non-alcoholic fatty liver disease -Cardiovascular disease | -Dietary supplement: N-acetyl cysteine 600 mg once/day -Dietary supplement: N-acetyl cysteine 600 mg twice/day -Other: placebo twice/day | -Nemours Children’s Clinic/Alfred I duPont Hospital, Jacksonville, Florida, United States |
16 | NCT02644239 | Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy | Unknown status | No results available | -Epilepsy -Cardiovascular disease -Non-alcoholic fatty Liver disease -Quality of life | Dietary supplement: ketogenic diet | Nagila Raquel Teixeira Damasceno, Sao Paulo, SP, Brazil |
17 | NCT02098317 | DHA and Vitamin D in Children With Biopsy-proven NAFLD | Completed | No results available | -NAFLD -Non-alcoholic steatohepatitis (NASH) | -Drug: DHA plus vitamin D -Drug: placebo | Bambino Gesù Children Hospital, Rome, Italy |
18 | NCT05073588 | Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children | Completed | No results available | Non-alcoholic fatty liver disease | -Other: Indo-Mediterranean diet -Other: calorie-restricted diet | -Institute of liver and biliary sciences, Delhi, India |
19 | NCT03883607 | Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH) | Terminated | Has results | Non-alcoholic steatohepatitis | -Drug: Elafibranor 80 mg -Drug: Elafibranor 120 mg | -University of California, San Diego, California, United States -Columbia University, New York, New York, United States |
20 | NCT00885313 | Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD) | Completed | No results available | -Fatty liver -Liver fibrosis -Obesity | -Drug: DHA250 -Drug: DHA500 -Drug: PLACEBO Behavioral: lifestyle intervention | Bambino Gesù Hospital and Research Institute, Rome, Italy |
21 | NCT04281121 | Omega 3 Supplementation in Children With Non Alcoholic Fatty Liver | Completed | No results available | Fatty liver | Dietary supplement: omega 3 fatty acids | Pediatrics hospital Ain shams University, Cairo, Egypt |
22 | NCT02548351 | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | Terminated | No results available | Non-alcoholic steatohepatitis (NASH) | Drug: Obeticholic acid Drug: placebo | The University of Alabama at Birmingham, Birmingham, Alabama, United States Digestive Health Specialists of the Southeast, Dothan, Alabama, United States |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mosca, A.; Pietrobattista, A.; Maggiore, G. Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics? Pediatr. Rep. 2024, 16, 288-299. https://doi.org/10.3390/pediatric16020025
Mosca A, Pietrobattista A, Maggiore G. Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics? Pediatric Reports. 2024; 16(2):288-299. https://doi.org/10.3390/pediatric16020025
Chicago/Turabian StyleMosca, Antonella, Andrea Pietrobattista, and Giuseppe Maggiore. 2024. "Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?" Pediatric Reports 16, no. 2: 288-299. https://doi.org/10.3390/pediatric16020025